ArticleTobacco regulatory science2020
An Analysis of the FTC's Attempt to Stop the Altria-Juul Labs Deal.
Article in Tobacco regulatory science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- How to Identify e-Cigarette Brands Available in the United States During 2020-2022: Development and Usability Study.JMIR formative research · 2024Article
- Do Tobacco Companies Have an Incentive to Promote "Harm Reduction" Products?: The Role of Competition.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Article
- A Decision-Theoretic Public Health Framework for Heated Tobacco and Nicotine Vaping Products.International journal of environmental research and public health · 2022Article
- The consequential impact of JUUL on youth vaping and the landscape of tobacco products: The state of play in the COVID-19 era.Preventive medicine reports · 2021Review
- Public health implications of vaping in the USA: the smoking and vaping simulation model.Population health metrics · 2021Article
- From Tobacco Cigarettes to Electronic Cigarettes: The Two Sides of a Nicotine Coin.Frontiers in oral health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
On 20 December 2018, Altria, the largest US cigarette company, announced an offer for a 35% share of the large and rapidly growing vaping product company, Juul Labs. On 2 April, 2020, the Federal Trade Commission issued a complaint that the deal was anticompetitive and should be voided. This paper analyzes the deal. We find that the deal gives Altria market power in the e-cigarette market through its support of Juul in retail stores and through the agreement not to otherwise compete in the e-cigarette market. The deal also has implications for its marketing of heated tobacco product IQOS and generally may provide Altria greater control of the broader nicotine delivery product market.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.